Efavirenz

GS-9770, atazanavir (ATV), darunavir (DRV), amprenavir (APV), bictegravir (BIC), elvitegravir (EVG), lenacapavir (LEN), tenofovir alafenamide (TAF), emtricitabine (FTC), efavirenz (EFV), stavudine (d4T), the RSV control inhibitor YM-53403, and the SARS CoV-2 control inhibitor remdesivir (RDV) were all synthesized at Gilead Sciences (Foster City, CA). Ribavirin (RBV) was purchased from Combi-Blocks (San Diego, CA). The protein synthesis inhibitor puromycin and the HIV-positive control azidothymidine (AZT) were purchased from Sigma-Aldrich (St. Louis, MO). The HBV control inhibitor ND-654 was purchased from Pharmaron (Beijing, China). The HCV protease inhibitor danoprevir was purchased from Selleck Chemicals (Houston, TX). All drug stocks were prepared in 100% dimethyl sulfoxide (DMSO) and stored frozen at −20°C.

Rabbit polyclonal antisera against HIV-1 CA, MA, NC, or IN were raised against purified recombinant proteins. Mouse monoclonal antibody 414, recognizing phenylalanine–glycine repeats of nuclear pore complex proteins, was from Abcam (UK); mouse monoclonal antibody against cytochrome C was from BD Biosciences (Franklin, NJ); affinity purified rabbit antibody against CPSF6 was obtained from Sigma (HPA039973). Secondary antibodies Alexa Fluor 405 Goat Anti-Mouse IgG, Alexa Fluor 532 Goat Anti-Rabbit IgG, and Alexa Fluor 568 Goat Anti-Rabbit IgG were from Life Technologies.
Stock solutions of 6 mM aphidicolin (Sigma A0781), 5 mM efavirenz (obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID), 10 mM PF74 (Gilead Sciences, Foster City, CA), and 10 mM elvitegravir (Gilead Sciences), respectively, were prepared in dimethyl sulfoxide (DMSO) and stored at −20°C.